CAHR's Industry-Renowned Market Access 101 Program

Emcee: Luisa Restrepo

Arvind Mani (Morse Consulting) Andrew Retfalvi (Global Public Affairs).
Market Access in Canada is a brood field encompassing many different areas. Join Arvind Mani and Andrew Retfalvi as they introduce the field including what market access entails in the Canadian market and provide on overview of what market access professionals need to know including an overview of the changing public policy landscape affecting the profession.

 

Judith Glennie (J.L Glennie Consulting Inc)
This session will focus on the data expectations of payers and HTA bodies as they evaluate/consider the value of new drug products for drug plan listing. In addition we will review the evolving role of real- world evidence (RWE) in reimbursement.

 

Anna Apostolakis (IQVIA)
New PMPRB Regulations will be implemented July 1st. The price rests and guidelines that will be used to operationalize the Regulations are in flux. This presentation will discuss what we know and what we need to watch for in terms of the review of new patented drugs.

 

Shanta Zurock (Innomar Strategies)
Join Shanta as she walks through a brief overview of private drug coverage in Canada: from where drugs fit overall into employer sponsored benefits to o discussion on the different types of management strategies insurers use to control drug costs.

 

Michelle Capon (GSK Canada)
This session will cover the basics of a Patient Support Program including why PSP’s are needed in Canada key elements of o PSP a typical PSP journey drug lifecycle considerations high level vendor landscape preparing for an REP and metrics to measure success.

Emcee: Jim Shea

Ferg Mills (Innomar Strategies)
A whirlwind tour of the planning and execution of the primary documents included in your submission dossiers. Parts 1 and 2 of the presentation will cover the timing of your activities strategic considerations and the building of the clinical evidence summary pharmacoeconomic analysis and budget impact analysis.

 

Ferg Mills (Innomar Strategies)

 

Bill Dempster (3Sixty Public Affairs)
This session will discuss how the pathway from bench to bedside for rare diseose medicines differs from common drugs and considerations to keep in mind at each level of the regulatory evaluation (HTA) negotiations (pCPA) and funding (public and private) for rare diseases.

 

 

 

 

Katherine Scott (Morse Consulting)
This session will provide an overview of the pan-Canadian Pharmaceutical Alliance (pCPA) including its history processes outcomes and outlook for the future.